Thymosin [thymalfasin] plus PEG-Interferon [peginterferon-α-2a] in hepatitis C patients with cirrhosis who did not respond to interferon or interferon plus ribavirin

Trial Profile

Thymosin [thymalfasin] plus PEG-Interferon [peginterferon-α-2a] in hepatitis C patients with cirrhosis who did not respond to interferon or interferon plus ribavirin

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2008

At a glance

  • Drugs Peginterferon alfa-2a; Thymalfasin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2008 Status changed from in progress to complete.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top